AMPHASTAR PHARMACEUTICALS IN (AMPH) Stock Price, Quote, News and Overview
NASDAQ:AMPH - Nasdaq - US03209R1032 - Common Stock - Currency: USD
AMPH Quote, Performance and Key Statistics
20.62
-1.08 (-4.98%)
The current stock price of AMPH is 20.62 USD. In the past month the price decreased by -18.63%. In the past year, price decreased by -47.94%.
AMPH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 56.08 | 731.38B | ||
| JNJ | JOHNSON & JOHNSON | 16.37 | 393.87B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 17.52 | 285.75B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.04 | 225.65B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 15.81 | 213.28B | ||
| MRK | MERCK & CO. INC. | 10.26 | 200.78B | ||
| PFE | PFIZER INC | 7.62 | 139.12B | ||
| SNY | SANOFI-ADR | 10.64 | 117.66B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.45 | 96.38B | ||
| GSK | GSK PLC-SPON ADR | 8.18 | 73.46B | ||
| ZTS | ZOETIS INC | 24.68 | 66.16B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 62.74 | 45.07B |
Related stock screener links
About AMPH
Company Profile
Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. The company is headquartered in Rancho Cucamonga, California and currently employs 2,028 full-time employees. The company went IPO on 2014-06-25. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The firm manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The firm manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.
Company Info
AMPHASTAR PHARMACEUTICALS IN
11570 6th St
Rancho Cucamonga CALIFORNIA 91730 US
CEO: Jack Y. Zhang
Employees: 2028
Phone: 19099809484
AMPHASTAR PHARMACEUTICALS IN / AMPH FAQ
What is the stock price of AMPHASTAR PHARMACEUTICALS IN today?
The current stock price of AMPH is 20.62 USD. The price decreased by -4.98% in the last trading session.
What is the ticker symbol for AMPHASTAR PHARMACEUTICALS IN stock?
The exchange symbol of AMPHASTAR PHARMACEUTICALS IN is AMPH and it is listed on the Nasdaq exchange.
On which exchange is AMPH stock listed?
AMPH stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AMPHASTAR PHARMACEUTICALS IN stock?
12 analysts have analysed AMPH and the average price target is 33.41 USD. This implies a price increase of 62% is expected in the next year compared to the current price of 20.62. Check the AMPHASTAR PHARMACEUTICALS IN stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AMPHASTAR PHARMACEUTICALS IN worth?
AMPHASTAR PHARMACEUTICALS IN (AMPH) has a market capitalization of 972.03M USD. This makes AMPH a Small Cap stock.
How many employees does AMPHASTAR PHARMACEUTICALS IN have?
AMPHASTAR PHARMACEUTICALS IN (AMPH) currently has 2028 employees.
What are the support and resistance levels for AMPHASTAR PHARMACEUTICALS IN (AMPH) stock?
AMPHASTAR PHARMACEUTICALS IN (AMPH) has a resistance level at 22.2. Check the full technical report for a detailed analysis of AMPH support and resistance levels.
Is AMPHASTAR PHARMACEUTICALS IN (AMPH) expected to grow?
The Revenue of AMPHASTAR PHARMACEUTICALS IN (AMPH) is expected to decline by -1.48% in the next year. Check the estimates tab for more information on the AMPH EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AMPHASTAR PHARMACEUTICALS IN (AMPH) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AMPH, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AMPH, evaluating the profitability, health, valuation and growth aspects
- AMPHASTAR PHARMACEUTICALS IN (AMPH) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AMPHASTAR PHARMACEUTICALS IN (AMPH) Sales and EPS estimates to see what analysts future expectations are.
- AMPHASTAR PHARMACEUTICALS IN (AMPH) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AMPHASTAR PHARMACEUTICALS IN (AMPH) Insider and Institutional Ownership to learn about the owners and their transactions.
- AMPHASTAR PHARMACEUTICALS IN (AMPH) Stock Chart to make your own analysis
- AMPHASTAR PHARMACEUTICALS IN (AMPH) Latest news and press-releases to stay up to date.
Does AMPHASTAR PHARMACEUTICALS IN (AMPH) stock pay dividends?
AMPH does not pay a dividend.
When does AMPHASTAR PHARMACEUTICALS IN (AMPH) report earnings?
AMPHASTAR PHARMACEUTICALS IN (AMPH) will report earnings on 2025-08-11, after the market close.
What is the Price/Earnings (PE) ratio of AMPHASTAR PHARMACEUTICALS IN (AMPH)?
The PE ratio for AMPHASTAR PHARMACEUTICALS IN (AMPH) is 5.79. This is based on the reported non-GAAP earnings per share of 3.56 and the current share price of 20.62 USD. Check the full fundamental report for a full analysis of the valuation metrics for AMPH.
What is the Short Interest ratio of AMPHASTAR PHARMACEUTICALS IN (AMPH) stock?
The outstanding short interest for AMPHASTAR PHARMACEUTICALS IN (AMPH) is 11.29% of its float. Check the ownership tab for more information on the AMPH short interest.
AMPH Technical Analysis
AMPH Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to AMPH. AMPH has an excellent profitability rating, but there are some minor concerns on its financial health.
AMPH Financial Highlights
Over the last trailing twelve months AMPH reported a non-GAAP Earnings per Share(EPS) of 3.56. The EPS decreased by -4.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 19.38% | ||
| ROA | 8.71% | ||
| ROE | 18.85% | ||
| Debt/Equity | 0.8 |
AMPH Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 77% to AMPH. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of -16.92% and a revenue growth -1.48% for AMPH